Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions

被引:41
作者
Koh, Seong-Ho [2 ]
Yoo, A. Rum [2 ]
Chang, Dae-Il [3 ]
Hwang, Se J. [1 ]
Kim, Seung H. [2 ]
机构
[1] Hanyang Univ, Coll Med, Dept Anat, Seoul 133791, South Korea
[2] Hanyang Univ, Coll Med, Dept Neurol, Seoul 133791, South Korea
[3] Kyung Hee Univ, Coll Med, Dept Neurol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
glycogen synthase kinase-3; ischemia; stroke; inflammation; neuronal cell death;
D O I
10.1016/j.bbrc.2008.05.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the present study, we have investigated the effects of glycogen synthase kinase-3 (GSK-3) inhibition on infarct volume and neurobehavioral functions in a focal cerebral ischemia model. To achieve our goals, GSK-3 inhibitor II or VIII was injected at several time points and in varing dosages. GSK-3 inhibitor VIII was more effective than inhibitor II, and infarct volume and water content in the VIII group were significantly decreased 24 h after the onset of ischemic stroke, as compared with the control group, These protective effects were associated with reductions of TUNEL-positive cells, neutrophil infiltration, glucose levels after ischemia, and GSK-3 enzyme activity. In addition, expressions of death and inflammation-related signals decreased and those of survival-related signals increased. Lastly, neurobehavioral functions were restored to a greater extent in the VIII group than in the control group. Together, these results suggest that GSK-3 inhibition reduces infarct volume and restores neurobehavioral functions. (C) 2008 Elsevier Inc. All rights reserved
引用
收藏
页码:894 / 899
页数:6
相关论文
共 13 条
[1]   AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test [J].
Gould, TD ;
Einat, H ;
Bhat, R ;
Manji, HK .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 (04) :387-390
[2]   Glycogen synthase kinase 3β inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia [J].
Kelly, S ;
Zhao, H ;
Sun, GH ;
Cheng, DY ;
Qiao, YL ;
Luo, J ;
Martin, K ;
Steinberg, GK ;
Harrison, SD ;
Yenari, MA .
EXPERIMENTAL NEUROLOGY, 2004, 188 (02) :378-386
[3]   Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model [J].
Koh, SH ;
Chang, DI ;
Kim, HT ;
Kim, J ;
Kim, MH ;
Kim, KS ;
Bae, I ;
Kim, H ;
Kim, DW ;
Kim, SH .
TOXICOLOGY, 2005, 214 (1-2) :131-139
[4]   The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals [J].
Koh, SH ;
Park, Y ;
Song, CW ;
Kim, JG ;
Kim, K ;
Kim, J ;
Kim, MH ;
Lee, SR ;
Kim, DW ;
Yu, HJ ;
Chang, DI ;
Hwang, SJ ;
Kim, SH .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2004, 20 (06) :1461-1472
[5]   Glycogen synthase kinase-3β activity plays very important roles in determining the fate of oxidative stress-inflicted neuronal cells [J].
Lee, Kyu-Yong ;
Koh, Seong-Ho ;
Noh, Min Young ;
Park, Kun-Woo ;
Lee, Young Joo ;
Kim, Seung Hyun .
BRAIN RESEARCH, 2007, 1129 (01) :89-99
[6]   REVERSIBLE MIDDLE CEREBRAL-ARTERY OCCLUSION WITHOUT CRANIECTOMY IN RATS [J].
LONGA, EZ ;
WEINSTEIN, PR ;
CARLSON, S ;
CUMMINS, R .
STROKE, 1989, 20 (01) :84-91
[7]   Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors [J].
Nærum, L ;
Norskov-Lauritsen, L ;
Olesen, PH .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (11) :1525-1528
[8]   Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway [J].
Pap, M ;
Cooper, GM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (32) :19929-19932
[9]   Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword? [J].
Patel, S ;
Doble, B ;
Woodgett, JR .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 :803-808
[10]   GSK-3α regulates production of Alzheimer's disease amyloid-β peptides [J].
Phiel, CJ ;
Wilson, CA ;
Lee, VMY ;
Klein, PS .
NATURE, 2003, 423 (6938) :435-439